BIOTHEUS - Key Persons

Job Titles:

• Co - Founder
• CSO
• Director
• Co - Founder, CSO )

Andy is responsible for Discovery Biology at Biotheus. He obtained his D. Phil. (Ph. D.) from the University of Oxford, and worked as a Postdocotoral Research Scientist/Associate Professor at Institut Pasteur of Shanghai before moving into industry. Andy was previously the Director of Functional Biology at Innovent Biologics, where he was responsible for target selection and lead molecule selection/characterization. During this period, he participated and led the discovery and development of sintilimab until IND filing. Andy also led the discovery and development of multiple therapeutic antibodies to other targets such as OX40, CD47, and LAG-3. Current CSO of Biotheus. Ph.D., University of Oxford, UK, post-doctorate at the Shanghai Pasteur Institute of the Chinese Academy of Sciences. Served as Associate Professor at the Shanghai Pasteur Institute of the Chinese Academy of Sciences and lead three National Natural Science Foundation projects as SME. As the core scientist of the joint research project between Chinese Academy of Sciences and international pharmaceutical companies, he has published nearly 35 papers in international academic journals. Andy was once the Director New Drug Research of Innovent Biologics, responsible for the functional biology research of new tumor immunotherapy antibody drugs. During this period, as the deputy project leader, he participated and led the whole process from drug discovery, cell line development to clinical trial application of the anti-tumor antibody drug PD-1 antibody-Sintilimab. Andy also led the discovery and development of multiple therapeutic antibodies such as OX40, CD47 and LAG-3.

Job Titles:

• Director

Managing Director of Legend Capital, emphasizing on the investment in medical healthcare, particularly in medical services and IT. Jianfei has led and participated in projects including EasyDiagnosis (002932.SZ), CareRay (688607.SH), Xihua Scientific, Shengsheng Logistics, Zhixiang Biological, Quest Life Science, Asia Medicare Group, and Safe Pharmaceutical Technology, etc. Jianfei holds an engineering bachelor's degree from Shanghai Jiaotong University and a management master's degree from Tsinghua University.

Job Titles:

• Vice President of Finance

Jinbo is the Vice President of Finance at Biotheus. He holds an MBA from The University of Quebec. He previously served as Vice President of Finance at Alphamab, CFO at Sanpower Biomedical, Vice President of Finance at Innovent Biologics, and Vice President of Finance at Hisun Pfizer. Jinbo has more than 20 years of experience in financial management, cost control, financing, taxation, IPO filing, etc. Jinbo helped Hisun Pfizer to establish its financial accounting and control system. During his work at Innovent Biologics, he led the C and D rounds of financing. At Alphamab, he played a large role in the structural reorganization listing on the Hong Kong Stock Exchange.

Job Titles:

• Co - Founder
• CTO
• Director

Joanne Sun is responsible for Discovery Technologies and CMC Development. Joanne obtained her Ph.D. from Brandeis University in the US and her Post-Doctoratal training at Harvard Medical School. Joanne has more than 20 years of rich experience in quality research and quality control in antibody discovery, development and commercial launching. She has successively served R&D executive positions at Abbott, Bristol-Myers Squibb, Adimab, etc., and participated in the development and quality research of many international best-selling biologics. After returning to China in 2012, she served as Vice President of Innovent Biologics, where she successfully established and led quality, analytical, and translational medicine teams, and made significant contributions to the establishment of their quality system.

Job Titles:

• CMO

Jonathan is responsible for clinical research and development. He has more than 20 years of experience in clinical development in oncology, diabetes, respiratory, infectious, autoimmune, cardiovascular, hematological and ophthalmic diseases. Joanathan has previously served at Pfizer and Boehringer Ingelheim, and led many global multi-center clinical trials. He has also served as SVP of clinical development at Innovent Biologics, Vice Executive President and CMO of BetaPharma.

Jun Bao is responsible for Business Development. He obtained his Ph.D. from the University of Kansas, his Postdocotoral training at Johns Hopkins and MBA from the University of Chicago. Dr. Bao has more than 20 years of comprehensive experience in the production and research, extensive experience in drug research and development, technology transfer, licensing and business development, venture investment, entrepreneurship and corporate finance. He has previously served as President & CEO at IMPACT Therapeutics. He also served as SVP & CBO at Shenogen Pharma, Director of Worldwide BD & Head of China BD at GSK，Director of Corporate Development and Financial Planning at Onyx. Moreover, in Seattle, he worked at ICOS Corporation and Cell Therapeutics as a business development executive with progressive responsibilities.

Roland is responsible for Business Development for ex-China. He has a Ph. D. and trained as a postdoctoral scientist in organic chemistry from the University of Rostock. Roland previously served as the Senior Director of Business Development at Celonic AG, Head of SPDC at NextPharma, Belgium, Manager of Contract Manufacturing at Miltenyi Biotec GmbH, and Project Manager for medical device development with PlasmaSelect.

Job Titles:

• Director

Managing Partner of Shiyu Capital. Ph.D. in Psychology from Shaanxi Normal University, Master's Supervisor, EMBA from School of Economics and Management of Tsinghua University. Simon has rich career experience and was engaged in Department of Human Resources And Social Security of Shaanxi Province in his early career. After entering the pharmaceutical and healthcare industry, he has worked for Johnson & Johnson, Gloria Pharmaceuticals, Jemincare and other well-known domestic and international companies, serving as vice president and other senior management positions, responsible for strategy, operations, corporate culture, branding, public relations and human resources. As a founding partner, Simon has more than two years of experience in high-end medical device startups, successfully achieving registration approval and commercialization of core products.

Job Titles:

• Director

CEO of HLC (Highlight Capital). Previously enrolled at USTC (University of Science and Technology of China), NYU (New York University), and LBS (London Business School). Once served in CHD, Avenue Capital (USA), Lehman Brothers (London Branch), and Becton Dickinson Healthcare Group (USA). Steven founded HLC in 2014 and manages 6 dual-currency funds (RMB/USD) a total of more than RMB 12 billion. His investment projects include Yuwell (002223), Wuxi Apptech (603259), Nayuki (02150), Mindray (300760), Pharmaron (300759), Tigermed (03347), Bright Gene (688166) and United Imagine, etc. He was awarded as Top 10 Best Investors in Healthcare in China for 2014-2019, Forbes Best Venture Capitalist in China for 2019, Top 100 Investor of Zero2IPO Investment Community in 2020.

Job Titles:

• CEO
• Chairman
• Member of the Management Team
• Co - Founder, Chairman & CEO )

As Chairman and CEO of Biotheus, Xiaolin has over 20 years of experience in antibody discovery and development. Previously, Xiaolin served in R&D roles at Abbott, Bristol-Myers Squibb and Adimab. In 2012, Xiaolin was appointed as Vice President of R&D at Innovent Biologics where he led an R&D team of more than 100 scientists, and created a product development pipeline of more than 20 novel antibody-based assets. As the project leader, he successfully oversaw the discvoery, development and and launch of Tyvyt (sintilimab) on the Chinese market.

Responsible for quality analysis. Doctor of Michigan State University, USA, Postdoctoral of University of Texas Southwestern Medical Center. Yingda has published more than 20 SCI papers, and presented reports at international conferences such as PEGS and AET several times. As senior researcher in Bristol-Myers Squibb Company (BMS), Yingda was responsible for analysis and development of Orencia Post Marketing Commitment for the FDA. He successfully developed a tryptic peptide mapping method for the quantification of Orencia oxidative deamination products, and the application of this method in the batch release quality control environment was quickly verified. In 2008, he served as the R&D executive of Adimab company and established what is now known as the world's first-class antibody discovery platform by yeast display technology.

Job Titles:

• Director
• Vice President at General Atlantic

Yumeng Wang is a vice president at General Atlantic, primarily responsible for investments in healthcare and life sciences sectors. Prior to joining General Atlantic, Ms. Wang served as an equity research analyst at The Hongkong and Shanghai Banking Corporation, mainly focusing on the healthcare sector. Ms. Wang also serves as a non-executive director of Ocumension Therapeutics (1477.HK) and Adagene Inc (NASDAQ: ADAG). Ms. Wang received her bachelor's degree in business administration in 2013 and her master's degree in biotechnology in 2021 from The Hong Kong University of Science and Technology.